Berenberg Bank Reiterates Hikma Pharmaceuticals PLC

Berenberg Bank reiterated a "Buy" rating on Hikma Pharmaceuticals PLC (OTCPK:HKMPY), setting an average one-year price target of $70.48 per share, which implies a 40.67% upside from its current $50.10 closing price. This positive analyst sentiment contrasts with projected annual revenue decreasing by 10.45% to $2.88 billion and an expected non-GAAP EPS of $2.12. Institutional activity shows a nuanced picture, with the number of reporting funds stable and average portfolio weight increasing by 4.90%, even as total institutional shares owned decreased by 11.43% to 16,000 shares.

Analysis

Berenberg Bank reiterated a 'Buy' recommendation for Hikma Pharmaceuticals PLC (OTCPK:HKMPY) on October 16, 2025, establishing an average one-year price target of $70.48 per share. This target implies a substantial 40.67% upside from the latest reported closing price of $50.10, with forecasts ranging from $59.95 to $81.86. This optimistic analyst outlook is presented despite a projected annual revenue decrease of 10.45% to $2.88 billion and an expected non-GAAP EPS of $2.12.

Institutional activity for HKMPY presents a nuanced picture. While the number of funds reporting positions remained unchanged at one, and the average portfolio weight dedicated to HKMPY increased by 4.90% to 1.14%, total institutional shares owned decreased by 11.43% to 16,000 shares over the last three months. Specifically, PENN MUTUAL AM 1847 INCOME FUND I (PMEFX) reduced its holdings by 12.90%, decreasing its portfolio allocation in HKMPY by 4.90%.

The divergence between a strong analyst 'Buy' rating and significant price target upside, contrasted with a projected revenue decline and a decrease in total institutional shares owned, warrants careful consideration. This mixed signal suggests that while analysts see considerable value, some institutional investors may be reducing exposure or rebalancing portfolios. The projected revenue contraction is a key fundamental point that stands in contrast to the bullish price target.

Key Decisions for Investors

• Investors should critically evaluate the analyst's 40.67% upside projection against the projected 10.45% annual revenue decrease to understand the underlying drivers of future value.
• Monitor upcoming earnings reports and management commentary for insights into the revenue decline and potential catalysts that could justify the bullish price target.
• Consider the mixed institutional sentiment, where increased portfolio weighting by existing funds contrasts with an overall reduction in total shares owned, indicating potential profit-taking or re-evaluation by some holders.